Dario A. Paggiarino - 23 Jan 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Medical Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
23 Jan 2024
Net transactions value
-$196,411
Form type
4
Filing time
25 Jan 2024, 18:26:21 UTC
Previous filing
10 Jan 2024
Next filing
29 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $40,650 +3,096 +8.5% $13.13 39,601 23 Jan 2024 Direct
transaction EYPT Common Stock Options Exercise $26,303 +2,039 +5.1% $12.90 41,640 23 Jan 2024 Direct
transaction EYPT Common Stock Sale $50,975 -2,039 -4.9% $25.00 39,601 23 Jan 2024 Direct
transaction EYPT Common Stock Sale $77,400 -3,096 -7.8% $25.00 36,505 23 Jan 2024 Direct
transaction EYPT Common Stock Options Exercise $72,898 +5,651 +15% $12.90 42,156 24 Jan 2024 Direct
transaction EYPT Common Stock Options Exercise $73,528 +5,600 +13% $13.13 47,756 24 Jan 2024 Direct
transaction EYPT Common Stock Sale $140,052 -5,600 -12% $25.01 42,156 24 Jan 2024 Direct F1
transaction EYPT Common Stock Sale $141,363 -5,651 -13% $25.02 36,505 24 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -3,096 -5.1% $0.000000 57,204 23 Jan 2024 Common Stock 3,096 $13.13 Direct F2
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -2,039 -8.3% $0.000000 22,586 23 Jan 2024 Common Stock 2,039 $12.90 Direct F3
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -5,600 -9.8% $0.000000 51,604 24 Jan 2024 Common Stock 5,600 $13.13 Direct F2
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -5,651 -25% $0.000000 16,935 24 Jan 2024 Common Stock 5,651 $12.90 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.14. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2021 and the remainder ratably, on a monthly basis, over the remaining three years.
F3 The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020